These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 6197639)

  • 1. Peptide neurotransmitters and their implications for the treatment of tardive dyskinesia.
    Blum I; Korczyn AD
    Mod Probl Pharmacopsychiatry; 1983; 21():187-95. PubMed ID: 6197639
    [No Abstract]   [Full Text] [Related]  

  • 2. Enkephalin, morphine, and naloxone in tardive dyskinesia.
    Bjørndal N; Casey DE; Gerlach J
    Psychopharmacology (Berl); 1980; 69(2):133-6. PubMed ID: 6779305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naloxone and naltrexone in mental illness and tardive dyskinesia.
    Volavka J; Anderson B; Koz G
    Ann N Y Acad Sci; 1982; 398():97-102. PubMed ID: 6760771
    [No Abstract]   [Full Text] [Related]  

  • 4. Cyclo(Leu-Gly): a possible treatment for tardive dyskinesia?
    Bhargava HN
    Mod Probl Pharmacopsychiatry; 1983; 21():196-205. PubMed ID: 6656783
    [No Abstract]   [Full Text] [Related]  

  • 5. Central administration of the neurotensin receptor antagonist SR48692 attenuates vacuous chewing movements in a rodent model of tardive dyskinesia.
    McCormick SE; Stoessl AJ
    Neuroscience; 2003; 119(2):547-55. PubMed ID: 12770567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melatonin mediates the antidyskinetic effects of naloxone in tardive dyskinesia.
    Sandyk R; Fisher H
    J Clin Psychopharmacol; 1989 Apr; 9(2):147-8. PubMed ID: 2723133
    [No Abstract]   [Full Text] [Related]  

  • 7. Neuropeptides and monoaminergic neurotransmitters: their relation to pain.
    Sweet WH
    J R Soc Med; 1980 Jul; 73(7):482-91. PubMed ID: 6164791
    [No Abstract]   [Full Text] [Related]  

  • 8. Naloxone, tardive dyskinesia, and endogenous beta-endorphin.
    Reker D; Anderson B; Yackulic C; Cooper TB; Banay-Schwartz M; Leon C; Volavka J
    Psychiatry Res; 1982 Dec; 7(3):321-4. PubMed ID: 6298849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine, GABA, cholecystokinin and opioids in neuroleptic-induced tardive dyskinesia.
    Ebadi M; Hama Y
    Neurosci Biobehav Rev; 1988; 12(3-4):179-87. PubMed ID: 2906420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naloxone in tardive dyskinesia.
    Blum I; Nisipeanu PF; Roberts E
    Psychopharmacology (Berl); 1987; 93(4):538. PubMed ID: 3124188
    [No Abstract]   [Full Text] [Related]  

  • 11. [Neuropeptides-neuromodulation].
    Astarloa R; Gobernado JM; Alvarez-Cermeño LC
    Neurologia; 1987; 2(3):114-22. PubMed ID: 2484062
    [No Abstract]   [Full Text] [Related]  

  • 12. [Neuroleptic parkinsonism and tardive dyskinesia and methods of pharmacologically correcting these pathologic conditions (review)].
    Arushanian EB
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1985; 85(2):269-77. PubMed ID: 2858951
    [No Abstract]   [Full Text] [Related]  

  • 13. High-dose destyrosine-gamma-endorphin in tardive dyskinesia.
    Korsgaard S; Casey DE; Gerlach J
    Psychopharmacology (Berl); 1982; 78(3):285-6. PubMed ID: 6130557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropeptides of the gut: a newly discovered major control system.
    Polak JM; Bloom SR
    World J Surg; 1979 Aug; 3(4):393-405. PubMed ID: 42225
    [No Abstract]   [Full Text] [Related]  

  • 15. Tardive dyskinesia: a role for the endogenous opioid system.
    Sandyk R
    Med Hypotheses; 1986 Jan; 19(1):71-4. PubMed ID: 2871480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neural activation of opioid mechanisms in guinea pig ileum by excitatory peptides.
    Garzón J; Höllt V; Sánchez-Blázquez P; Herz A
    J Pharmacol Exp Ther; 1987 Feb; 240(2):642-9. PubMed ID: 2433432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Putative peptide neurotransmitters in human neuropathology: a review of topography and clinical implications.
    Constantinidis J; Bouras C; Richard J
    Clin Neuropathol; 1983; 2(2):47-54. PubMed ID: 6189657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Peptide neuroregulators in the central nervous system].
    Lutz W; Chmielewski H; Pawlak J
    Neurol Neurochir Pol; 1984; 18(1):43-50. PubMed ID: 6203045
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacologic probes of neurotransmitter systems in tardive dyskinesia: implications for clinical management.
    Nasrallah HA; Dunner FJ; McCalley-Whitters M; Smith RE
    J Clin Psychiatry; 1986 Feb; 47(2):56-9. PubMed ID: 3003037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Failure of high dose naloxone to relieve tardive dyskinesia.
    Newhouse PA; Tariot PN; Gross M; Murphy DL; Cohen RM
    J Clin Psychopharmacol; 1987 Oct; 7(5):364-5. PubMed ID: 3680616
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.